Ficerafusp Alfa Shows Doubled 3-Year OS in HNSCC Phase 1/1b Study, Reinforcing Phase 3 Potential
BCAX has more than doubled off its 52-week low of $7.8.
Summary
Bicara Therapeutics reported positive three-year follow-up data for ficerafusp alfa in HNSCC, showing significantly improved overall survival and deep, durable responses, which supports its ongoing Phase 3 trial.
Key Events · Product Development and Regulatory · BCAX
-
Compelling 3-Year OS Data
Ficerafusp alfa in combination with pembrolizumab demonstrated an estimated 31% overall survival at three years in 1L R/M HPV-negative HNSCC, approximately doubling the survival rate observed with standard of care.
-
Deep and Durable Responses
The Phase 1/1b study showed deep, durable responses, with complete response rates increasing across dose cohorts (up to 30%). Deep responders experienced significantly longer duration of response, progression-free survival, and overall survival.
-
Mechanistic Confirmation
Biomarker analyses reinforced that TGF-β inhibition is the mechanistic foundation for the observed clinical benefits, driving tumor penetration and immune activation.
-
Supports Pivotal Phase 3 Study
These positive long-term results reinforce the potential of ficerafusp alfa, which is currently being evaluated in the pivotal Phase 3 FORTIFI-HN01 study for the same indication and holds Breakthrough Therapy Designation.
Analysis · BCAX · Life Sciences
Bicara Therapeutics announced compelling three-year follow-up data from its Phase 1/1b study of ficerafusp alfa in combination with pembrolizumab for first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma (HNSCC). The data demonstrated an estimated 31% overall survival at three years for the 1500mg QW dose, approximately doubling the survival rate compared to standard of care. This strong long-term efficacy, including deep and durable responses driven by TGF-β inhibition, significantly de-risks the ongoing pivotal Phase 3 FORTIFI-HN01 study and reinforces the drug's Breakthrough Therapy Designation, indicating a potentially transformative treatment for a difficult-to-treat cancer.
At the time of this filing, BCAX was trading at $20.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $7.80 to $24.25. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.